Pharmather Hldgs Ltd (PHRRF)

$0.16 -0.01 (-3.18%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 73,612
Avg Vol 207,928
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 70%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 888-846-3171
Address:
82 Richmond Street East, Toronto, Canada
John_morris
John_morris Jun. 16 at 7:32 PM
$PHRRF The CEO is busy cheering other stocks on Twitter. Hope he has PHRRF in his thoughts - both when he is awake and in his dreams and working to deliver the goods. https://x.com/FabioChianelli/status/1934659254322950373
0 · Reply
buymoremakemore
buymoremakemore Jun. 13 at 6:29 PM
$PHRRF 30k shares. Worth the $5000 risk lol. If this gets approved, not only will this rise heavily on OTC, they can take the party back to NASDAQ for more eyeballs and buying pressure from tutes. They can be instrumental in the USA ketamine shortage and be profitable with tens of millions on revenue. Game on!
3 · Reply
John_morris
John_morris Jun. 11 at 9:12 PM
$PHRRF Watch from 29.45 Minutes https://www.youtube.com/watch?v=PDfByp3al7E
0 · Reply
Johnm_
Johnm_ Jun. 11 at 3:56 PM
$PHRRF - Gearing up.
0 · Reply
Johnm_
Johnm_ Jun. 11 at 2:11 PM
$PHRRF Loading..
0 · Reply
Amb8675309
Amb8675309 Jun. 11 at 1:43 PM
$PHRRF nice pop today- any news I’m missing?
1 · Reply
StocksInvestorGirl
StocksInvestorGirl Jun. 3 at 5:07 PM
$PHRRF 🚨 $PHRRF / $PHRM ALERT! 🚨 🔥 FDA Approval Goal Date: August 9, 2025 💊 KETARX™ (Ketamine) – Addressing U.S. drug shortages 📈 Analyst Price Target: C$5.00 (H.C. Wainwright) 💥 Massive upside potential from current levels 🔬 Why it matters: Priority review granted for minor amendment No new clinical studies required 18-month stability achieved without issues No additional deficiencies reported by FDA 📊 Market Cap: ~C$19M 💼 Float: ~72M shares 📅 Approval expected: On or before August 9, 2025 💡 Key takeaway: PharmaTher is poised to become a leading supplier of FDA-approved ketamine in the U.S., addressing a critical shortage and unlocking significant market potential.
1 · Reply
Moneymaknmarsh
Moneymaknmarsh May. 29 at 7:13 PM
$PHRRF Grok - % chance of Pharmather KETARX/Ketamine approval by 8.09.2025, 70% - 80% Seem about right? GLTA Good Luck Making Money
1 · Reply
Johnm_
Johnm_ May. 29 at 4:12 PM
$PHRRF https://www.pharmather.com/ketavault.html
0 · Reply
Johnm_
Johnm_ May. 28 at 2:20 PM
$PHRRF PharmaTher’s Ketamine Drug Review Extended by FDA https://www.tipranks.com/news/company-announcements/pharmathers-ketamine-drug-review-extended-by-fda
0 · Reply
Latest News on PHRRF
No data available.
John_morris
John_morris Jun. 16 at 7:32 PM
$PHRRF The CEO is busy cheering other stocks on Twitter. Hope he has PHRRF in his thoughts - both when he is awake and in his dreams and working to deliver the goods. https://x.com/FabioChianelli/status/1934659254322950373
0 · Reply
buymoremakemore
buymoremakemore Jun. 13 at 6:29 PM
$PHRRF 30k shares. Worth the $5000 risk lol. If this gets approved, not only will this rise heavily on OTC, they can take the party back to NASDAQ for more eyeballs and buying pressure from tutes. They can be instrumental in the USA ketamine shortage and be profitable with tens of millions on revenue. Game on!
3 · Reply
John_morris
John_morris Jun. 11 at 9:12 PM
$PHRRF Watch from 29.45 Minutes https://www.youtube.com/watch?v=PDfByp3al7E
0 · Reply
Johnm_
Johnm_ Jun. 11 at 3:56 PM
$PHRRF - Gearing up.
0 · Reply
Johnm_
Johnm_ Jun. 11 at 2:11 PM
$PHRRF Loading..
0 · Reply
Amb8675309
Amb8675309 Jun. 11 at 1:43 PM
$PHRRF nice pop today- any news I’m missing?
1 · Reply
StocksInvestorGirl
StocksInvestorGirl Jun. 3 at 5:07 PM
$PHRRF 🚨 $PHRRF / $PHRM ALERT! 🚨 🔥 FDA Approval Goal Date: August 9, 2025 💊 KETARX™ (Ketamine) – Addressing U.S. drug shortages 📈 Analyst Price Target: C$5.00 (H.C. Wainwright) 💥 Massive upside potential from current levels 🔬 Why it matters: Priority review granted for minor amendment No new clinical studies required 18-month stability achieved without issues No additional deficiencies reported by FDA 📊 Market Cap: ~C$19M 💼 Float: ~72M shares 📅 Approval expected: On or before August 9, 2025 💡 Key takeaway: PharmaTher is poised to become a leading supplier of FDA-approved ketamine in the U.S., addressing a critical shortage and unlocking significant market potential.
1 · Reply
Moneymaknmarsh
Moneymaknmarsh May. 29 at 7:13 PM
$PHRRF Grok - % chance of Pharmather KETARX/Ketamine approval by 8.09.2025, 70% - 80% Seem about right? GLTA Good Luck Making Money
1 · Reply
Johnm_
Johnm_ May. 29 at 4:12 PM
$PHRRF https://www.pharmather.com/ketavault.html
0 · Reply
Johnm_
Johnm_ May. 28 at 2:20 PM
$PHRRF PharmaTher’s Ketamine Drug Review Extended by FDA https://www.tipranks.com/news/company-announcements/pharmathers-ketamine-drug-review-extended-by-fda
0 · Reply
Tonyboner
Tonyboner May. 27 at 2:19 PM
$PHRRF
0 · Reply
Johnm_
Johnm_ May. 27 at 12:07 PM
$PHRRF Update : https://x.com/FabioChianelli/status/1927132214254350358
0 · Reply
skylinexplorer
skylinexplorer May. 22 at 8:32 PM
$PHRRF slowly getting back up! come on
1 · Reply
Johnm_
Johnm_ May. 22 at 12:47 PM
$ALLR On Breakout watch $GNLX $PHRRF $XBI $PRPH
0 · Reply
Johnm_
Johnm_ May. 21 at 6:38 PM
$PHRRF -
0 · Reply
Johnm_
Johnm_ May. 21 at 12:06 PM
$ALLR - Trending $XBI $GNLX $PHRRF $PRPH -
0 · Reply
Tonyboner
Tonyboner May. 19 at 2:31 PM
$PHRRF So surprised this is not trading below 10c
1 · Reply
Amb8675309
Amb8675309 May. 16 at 5:51 PM
$PHRRF my understanding is if FDA moves a PDUFA out a few months it’s not necessarily a bad sign. They are saying they need more time. If they didn’t like what they were seeing at this point, they would just kill it with a CRL wouldn’t they? That’s what someone else( experienced BP executive and seasoned biotech investor)said in a video about investing in biotech. He said an extension of a PDUFA date is actually a positive, not a negative…
1 · Reply
dcajic2
dcajic2 May. 16 at 3:27 PM
$PHRRF Didn’t they clarify a minor amendment few months back and that is why they got the June 4 date. Very doubtful they will ever get FDA approval
3 · Reply
dcajic2
dcajic2 May. 16 at 3:25 PM
$PHRRF Pretty much the end of the road with this one. I did have hope. Why give them a goal date of June 4 and then say sorry goal date is now august 9
0 · Reply
Tonyboner
Tonyboner May. 16 at 1:37 PM
$PHRRF So glad I sold this into them buyers the last 2 days, PDUFA long way out now expect a bleed they will need some money soon, just my 2c
0 · Reply
John_morris
John_morris May. 16 at 12:51 PM
$PHRRF More Mess . . . "PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today announced the U.S. (FDA) has extended the approval goal date for the review of its new drug application for ketamine. The new approval goal date is August 9, 2025, revised from the previous date of June 4, 2025. The extension allows the FDA additional time to review additional information requests, which the FDA has classified as a MINOR amendment. Importantly, this is not a Complete Response Letter. "While we were prepared for a decision by June 4, 2025, we acknowledge the FDA's need for additional time to review our recent submission and additional information request for the ketamine new drug application," said Fabio Chianelli, CEO of PharmaTher. "We do not anticipate this extension to August 9, 2025, will materially impact our ongoing operational, business development, and commercialization initiatives for 2025."
1 · Reply